Live Breaking News & Updates on Relapsed Small Cell Lung Cancer

Stay updated with breaking news from Relapsed small cell lung cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial

. ....

United States , United Kingdom , Noord Holland , Suresh Senan , Susan Galbraith , Daiichi Sankyo , Lungevity Foundation , World Health Organization , International Agency For Research On Cancer , American Cancer Society , National Cancer Institute , Amsterdam University Medical Center , Lung Ambition Alliance , Executive Vice President , Fatal Immune Mediated Adverse , Mediated Nephritis , Stevens Johnson Syndrome , Full Prescribing Information , Medication Guide , South America , Rare Diseases , Cell Lung , Accessed April , Relapsed Small Cell Lung Cancer , Small Cell Lung Cancer , Mixed Methods Study ,

AstraZeneca : Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - Form 6-K -April 05, 2024 at 06:26 am EDT

A4121j

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or. ....

United Kingdom , United States , Noord Holland , Susan Galbraith , Astrazeneca Imfinzi , Adrian Kemp , Daiichi Sankyo , Suresh Senan , Lung Ambition Alliance , Company Secretary , Commission File Number , International Agency For Research On Cancer , National Cancer Institute , Securities Exchange , World Health Organization , Lungevity Foundation , Amsterdam University Medical Center , American Cancer Society , Investor Relations Team , Foreign Issuer , Securities Exchange Act , File Number , Crick Avenue , Regulationst Rule , Executive Vice President , South America ,

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
mynewsdesk.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mynewsdesk.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Astrazeneca Imfinzi , Daiichi Sankyo , Luis Paz , Susan Galbraith , European Society Of Medical Oncology , National Cancer Institute , World Health Organization , Lung Ambition Alliance , Company On Twitter Astrazeneca , Lungevity Foundation , Investor Relations Team , International Agency For Research On Cancer , Oncology Department , European Society , Medical Oncology , Scientific Program , Medical Oncology Department , Hospital Universitario , Executive Vice President , South America , Rare Diseases , International Agency , Lung Fact , Accessed September ,

AstraZeneca : IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

AstraZeneca : IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Daiichi Sankyo , Luis Paz , Susan Galbraith , National Cancer Institute , European Society Of Medical Oncology , Oncology Department , Lung Ambition Alliance , American Cancer Society , European Society , Medical Oncology , Scientific Program , Medical Oncology Department , Hospital Universitario , Executive Vice President , Thyroid Disorders , Immune Mediated Nephritis , Immune Mediated Dermatology , Stevens Johnson Syndrome , Prescribing Information , South America , Oncology Nurse Educator , Key Statistics , Accessed September , Small Cell Lung , Relapsed Small Cell Lung Cancer ,

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Imfinzi approved in China for extensive-stage SCLC

of extensive-stage small cell lung cancer

Only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies

AstraZeneca s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).

The approval by China s National Medical Products Administration was based on positive results from the CASPIAN Phase III trial. The trial showed that Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus chemotherapy alone. In addition, results from the China cohort of patients were consistent with the global results. ....

United Kingdom , United States , Dave Fredrickson , Astrazeneca Imfinzi , Daiichi Sankyo , Adrian Kemp , National Cancer Institute , World Health Organization , Lung Ambition Alliance , Company On Twitter Astrazeneca , Lungevity Foundation , China National Medical Products Administration , Investor Relations Team , International Agency For Research On Cancer , National Medical Products Administration , Executive Vice President , Oncology Business Unit , South America , Cell Lung , Accessed July , Relapsed Small Cell Lung Cancer , Lung Cancer , International Agency , Lung Fact , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் ,